Short-Course Radiotherapy-Based Total Neoadjuvant Therapy plus Tislelizumab for Locally Advanced Rectal Cancer (Neo-STAR): Early Outcomes of a Randomized Phase II Trial [0.03%]
短疗程放疗为基础的新辅助综合治疗联合泰斯利珠单抗用于局部晚期直肠癌的II期临床试验（Neo-STAR）初步结果
Fengpeng Wu,Xuhua Hu,Baokun Li et al.
Fengpeng Wu et al.
Background: Short-course radiotherapy (SCRT)-based total neoadjuvant therapy (TNT) is used for locally advanced rectal cancer (LARC). However, the pathological complete response (pCR) rate still hovers around 30%. Radiotherapy and immune ch...
Decoding the Malignant Potential of Hydatidiform Moles through Fibroblast and LAIR2 Signatures [0.03%]
通过成纤维细胞和LAIR2标志物解码葡萄胎恶性潜能
Chen Li,Zhiang Chen,Jiandong Chen et al.
Chen Li et al.
Excess Weight May Account for More Than 10% of All Cancers: The Underestimated Impact of the Obesity Epidemic [0.03%]
超重可能占所有癌症的10%以上：肥胖流行病的影响被低估了
Luna Kiran Adhikari,Fatemeh Safizadeh,Marko Mandic et al.
Luna Kiran Adhikari et al.
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study [0.03%]
白蛋白结合型紫杉醇（SYHX2011）治疗晚期乳腺癌的多中心、随机、双盲、三期临床试验
Lina Zhang,Jingxuan Wang,Tao Sun et al.
Lina Zhang et al.
Background: SYHX2011 is a novel albumin-bound paclitaxel, in which most nonparticulate human albumin is replaced with mannitol and sucrose. This study aimed to compare SYHX2011 and paclitaxel for injection (albumin-bound) (PAB) in patients ...
Loss of WNT2B Increases Tumor Burden and Malignant Features in Colorectal Cancer [0.03%]
WNT2B丢失增加结直肠癌肿瘤负荷和恶性特征
Luiz Fernando Silva Oliveira,Yu-Syuan Wu,Sathuwarman Raveenthiraraj et al.
Luiz Fernando Silva Oliveira et al.
Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences [0.03%]
免疫检查点抑制剂治疗后超进展：一个影响临床实践的现象
Damien Bruyat,Nicolas Girard,Pierre Heudel et al.
Damien Bruyat et al.
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study [0.03%]
斯鲁利单抗联合化疗对比单纯化疗一线治疗非鳞状非小细胞肺癌（ASTRUM-002）III期研究：最终总生存分析
Xuezhi Hao,Lin Wang,Yanrong Hao et al.
Xuezhi Hao et al.
Background: ASTRUM-002 met the primary endpoint of progression-free survival (PFS) with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. Here, we report the results of the final surviv...
Allan M Johansen,Julie T Ziegler,Kojo Agyemang et al.
Allan M Johansen et al.
Impact of China's Drug Regulatory Reforms on the Development of Anti-Tumor Drugs [0.03%]
中国医药改革对肿瘤药物研发的影响分析
Ling Tang,Lijia Yuan,Ying Geng et al.
Ling Tang et al.
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK- Positive Non-Small Cell Lung Cancer [0.03%]
性别通过药物暴露量影响ALK阳性非小细胞肺癌患者 Alecite닙 无进展生存期
Daan A C Lanser,Niels Heersche,M Benthe Muntinghe-Wagenaar et al.
Daan A C Lanser et al.